private_company

Cambrian Biopharma

Cambrian Biopharma is an investor based in the United States, investing in Software & Developer Tools, E-commerce Software and Retail Tech, 1 tracked investment.

View Full Profile Website

Investments Tracked

See full portfolio →

About Cambrian Biopharma

Operating out of the United States, Cambrian Biopharma is an investor. Our dataset covers 1 investment involving Cambrian Biopharma.

Recorded deals span Software & Developer Tools, E-commerce Software, Retail Tech and Machine Learning. Coverage extends to 8 sectors in total. Investments are concentrated at Series B.

Cambrian Biopharma operates as a distributed company (DisCo) with several subsidiaries that develop drugs targeting various healthspan-improving pathways. They aim to target the mechanistic drivers of aging through a multiple shots-on-goal approach.

Investment Focus

Stage Focus

series-b

Sectors

Software & Developer ToolsE-commerce SoftwareRetail Techmachine-learningaicomputer-visioncheckout-freeretail

Investment Thesis

Team

James PeyerCEO, Founder, Board Director

Chief Executive Officer and Founder of Cambrian Bio. Previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm.

Juliette HanChief Financial Officer & Chief Operating Officer

Chief Financial Officer and Chief Operating Officer at Cambrian Bio. Also adjunct professor at Columbia Business School. Previously Chief of Staff at Two Sigma Private Investments Group.

Mark NuttallChief Business Officer

Chief Business Officer at Cambrian Bio. Previously Chief Business Officer for Kintai Therapeutics/Senda Biosciences and Kymera Therapeutics.

Ruth Thieroff-EkerdtChief Medical Officer

Chief Medical Officer at Cambrian Bio. Over 30 years of experience in pharmaceutical R&D. Previously Chief Medical Officer at Sojournix and Acting CMO at Organon.

Bill DeVaulChief Legal Officer

Chief Legal Officer of Cambrian Bio. Previously General Counsel at Morphic Holding (acquired by Eli Lilly for $3.2B in 2024).

Christian AngermayerChairman, Co-Founder, Board Director

Chairman and Co-Founder of Cambrian Bio. Serial entrepreneur who raised over $1.6B for portfolio companies. Co-founder of Ribopharma (now Alnylam).

Maryanna SaenkoBoard Director

Co-Founder and Partner at Future Ventures. Previously Principal at Khosla Ventures and Senior Associate at DFJ.

Brenton L. SaundersBoard Director

Executive Chairman of The Beauty Health Company. Previously Chairman, President and CEO of Allergan. Also serves on Board of Directors of Cisco Systems and BridgeBio.

Paul FarrBoard Director

Co-founded and co-leads Anthos Capital. Previously investor with Summit Partners and investment banker with Goldman Sachs.

R. Martin ChavezBoard Observer

Partner and Vice Chairman of Sixth Street Partners. Previously Chief Information Officer and Chief Financial Officer at Goldman Sachs.

Steve JurvetsonBoard Observer

Early-stage venture capitalist focused on disruptive technology. Co-founder of Future Ventures and Draper Fisher Jurvetson. Board seats include SpaceX and Tesla.

Jessica AinscoughSenior Director, Clinical Operations

Senior Director of Clinical Operations for Cambrian Bio. Over 17 years of experience in clinical operations and quality management leadership.